Dana-Farber Cancer Institute and Harvard Medical School
Guru P. Sonpavde, MD is the Bladder Cancer Director at the Dana Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School. At Dana-Farber, he leads multiple cutting-edge clinical trials studying novel immunotherapy and targeted drugs to cure bladder cancer. He is the also the national or international Principal Investigator of multiple clinical trials of bladder cancer patients. Additionally, he is on the steering committees of several major clinical trials attempting to improve outcomes and change the standard of care of bladder cancer patients. He completed his medical oncology fellowship at Indiana University. His primary focus is clinical trials to develop new drugs and combinations to treat urologic cancers with a focus on bladder cancer. He has also led translational projects and developed prognostic classifications and clinical endpoints focused on bladder cancer. He is a member of Southwest Oncology Group (SWOG) and Bladder Cancer Task Force of the U.S. NCI GU Steering Committee.
AstraZenaca (Individual(s) Involved: Self; Clinical Condition: Bladder cancer): Consultant, Grant/Research Support, Other Financial or Material Support, Travel; Bicycle (Individual(s) Involved: Self; Clinical Condition: Bladder cancer): Consultant; BMS (Individual(s) Involved: Self; Clinical Condition: Bladder cancer): Consultant, Grant/Research Support, Other Financial or Material Support, Travel; Elsevier (Individual(s) Involved: Self; Clinical Condition: Bladder cancer): Editor of Bladder Cancer Practice Update center of excellence online, Other Financial or Material Support; EMD Serono (Individual(s) Involved: Self; Clinical Condition: Bladder cancer): Consultant; Exelixis (Individual(s) Involved: Self; Clinical Condition: prostate cancer): Advisory Board; G1 Therapeutics (Individual(s) Involved: Self; Clinical Condition: Bladder cancer): Consultant; Genentech (Individual(s) Involved: Self; Clinical Condition: Bladder cancer): Advisory Board; Immunomedics/Gilead (Individual(s) Involved: Self; Clinical Condition: Bladder cancer): Consultant, Grant/Research Support; Infinity Therapeutics (Individual(s) Involved: Self; Clinical Condition: Bladder cancer): Consultant; Janssen Pharmaceuticals (Individual(s) Involved: Self; Clinical Condition: Bladder cancer): Advisory Board, Grant/Research Support; Loxo Oncology/Lilly (Individual(s) Involved: Self; Clinical Condition: Bladder cancer): Consultant; Merck (Individual(s) Involved: Self; Clinical Condition: Bladder cancer): Advisory Board, Consultant; Mereo Therapeutics (Individual(s) Involved: Self; Clinical Condition: Bladder cancer): Data safety monitoring committee, Other Financial or Material Support; Myriad (Individual(s) Involved: Self; Clinical Condition: none): employer of spouse, Other Financial or Material Support; Pfizer Inc (Individual(s) Involved: Self; Clinical Condition: Bladder cancer): Consultant; Predicine Genomics (Individual(s) Involved: Self; Clinical Condition: Bladder cancer): Grant/Research Support; QED Therapeutics Inc (Individual(s) Involved: Self; Clinical Condition: Bladder cancer): Grant/Research Support; Sanofi US (Individual(s) Involved: Self; Clinical Condition: Bladder cancer): Grant/Research Support; Scholar Rock (Individual(s) Involved: Self; Clinical Condition: Bladder cancer): Consultant; Seattle Genetics, Inc. (Individual(s) Involved: Self; Clinical Condition: Bladder cancer): Consultant
Wednesday, March 9, 2022
12:50 PM – 3:20 PM
Wednesday, March 9, 2022
1:35 PM – 1:55 PM
Wednesday, March 9, 2022
2:35 PM – 3:20 PM